Frequency Therapeutics, Inc. (FREQ) reported the results from its FX-322-113 study, a placebo-controlled trial evaluating the administration of FX-322 in subjects with severe sensorineural hearing loss. In the study, FX-322 was associated with a hearing signal as shown by improvements by four subjects in a sentence-in-noise test.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

Frequency Therapeutics, Inc. (FREQ) reported the results from its FX-322-113 study, a placebo-controlled trial evaluating the administration of FX-322 in subjects with severe sensorineural hearing loss. In the study, FX-322 was associated with a hearing signal as shown by improvements by four subjects in a sentence-in-noise test.

RTTNews | Dec 9, 2021 08:15AM EST

08:15 Thursday, December 9, 2021 (RTTNews.com) - Frequency Therapeutics, Inc. (FREQ) reported the results from its FX-322-113 study, a placebo-controlled trial evaluating the administration of FX-322 in subjects with severe sensorineural hearing loss. In the study, FX-322 was associated with a hearing signal as shown by improvements by four subjects in a sentence-in-noise test.

"This is the third FX-322 study where we have observed a hearing signal, furthering our confidence in our clinical program and the potential of a regenerative treatment for sensorineural hearing loss," said David Lucchino, CEO.

Read the original article on RTTNews ( https://www.rttnews.com/3248144/frequency-therapeutics-fx-322-associated-with-hearing-signal-in-placebo-controlled-trial.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved